SAN DIEGO, April 28 /PRNewswire/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its distributor, BioTech Medical, LLC, is well-positioned to immediately respond to the current swine flu emergency with its SDC-based SpectraSan 24(TM) disinfectant. SpectraSan 24, which meets the recommendations by the United States Centers for Disease Control (CDC) for infection control for care of patients with confirmed or suspected Swine Influenza A (H1N1) virus in both home and healthcare settings.
Andrea L. Goren, Executive Director of BioTech Medical, LLC, stated, "We are prepared and well-positioned to supply a much needed preventative solution to this potentially dangerous swine flu outbreak. BioTech Medical has a long-term history of successfully selling innovative healthcare products through various market channels and representative groups to multiple segments of the healthcare industry, including hospitals, long-term care facilities, clinics and doctors' offices throughout the United States as well as internationally."
Ms. Goren continued, "In addition to our existing marketing organization, we have the staff, warehousing facilities, distribution capability and capital resources to rapidly deliver SpectraSan 24 to all facets of not only healthcare but also institutions, businesses and the hospitality industry. We also have entree into schools, day care, athletic facilities and all modes of transportation such as airlines, cruise lines, rail and bus lines including all regional transit authorities. We also intend to offer SpectraSan 24 directly to consumers and through retail outlets in conjunction with our parent company, SCI Industries."
According to the CDC, person-to-person transmission of flu occurs mainly through coughing or sneezing of people infected with the influenza virus. People may become infected by touching something with the flu viruses on it and then touching their mouths or noses. Guidance published by the CDC on April 24, 2009 for infection control in healthcare settings advises that "disinfection strategies used during influenza seasons can be applied to the environmental management of swine influenza." Additional guidance published on April 25, 2009 for infection control in the home recommends keeping "surfaces (especially bedside tables, surfaces in the bathroom, and toys for children) clean by wiping them down with a household disinfectant according to directions on the product label."
PURE's SDC-based disinfectants have been registered by the EPA specifically for use on children's toys, cribs, high chairs and other sensitive areas of the home as well as for use on hard surfaces in multitudes of environments, including hospitals, schools and offices.
SpectraSan 24's broad spectrum power completely and rapidly eliminates bacteria, fungi and viruses, including Influenza A. SpectraSan 24 also carries a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a 2-minute kill time on some resistant strains of bacteria, a 10-minute kill time on fungi, a 30-second kill time on HIV Type I, and 10-minute kill times on other pathogenic viruses. These claims distinguish the efficacy of SpectraSan 24 from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, SpectraSan 24 is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.
About BioTech Medical, LLC
BioTech Medical, LLC is a North Canton, Ohio based division of privately-held SCI Industries, a leading international marketing company. SCI distributes hundreds of diversified products around the world and has established its success through product innovation and multi-channel marketing. BioTech Medical's multiple business segments are each focused on the distribution of innovative healthcare products, including the SDC-based SpectraSan 24 and Cruise Control hard surface disinfectants. For more information, please visit www.biotechmedicalllc.com.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
|SOURCE BioTech Medical, LLC|
Copyright©2009 PR Newswire.
All rights reserved